Skip to main content

Table 1 Baseline characteristics of patients with polypoidal choroidal vasculopathy who were treated with a fixed-dosing intravitreal aflibercept regimen

From: One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient

 

All

Pre-treated

Treatment-naïve

P value

Pre-treated vs. Treatment-naïve

Numbers (eyes)

25

13

12

 

Age (years)

67.16±8.20

67.2±5.44

67.12±10.7

0.983 a

Sex (male: female)

20: 5

9:4

11:1

0.161b

Laterality (right: left)

15: 10

7:6

8:4

0.513b

Best Corrected Visual acuity

 Snellen

0.53±0.31

0.52±0.33

0.54±0.30

0.841 a

 ETDRS letters

65.48±15.43

64.46±16.52

66.58±14.79

0.739 a

Central macular thickness (μm)

406.92±159.36

356.08±145.58

462±160.99

0.097 a

Location of vascular lesion (eyes)

 Subfoveal

15 (60.0%)

7 (53.8%)

8 (66.6%)

0.566c

 Juxtafoveal

9 (36.0%)

5 (38.5%)

4 (33.3%)

 Extrafoveal

1 (4.0%)

1 (8%)

0 (0%)

Area of branching vascular network (mm2)

3.12±1.98

3.66±2.18

2.11±1.02

0.045a

Numbers of polypoidal lesions

2.60±1.68

3.30±1.88

1.83±1.02

0.025a

Height of the largest polypoidal lesion (μm)

345.64±159.44

331.84±134.21

360.58±187.99

0.662 a

Location of the polyp closest to the foveal center (eyes)

 Subfoveal

11 (44.0%)

3 (23.0%)

8 (66.6%)

0.004c

 Juxtafoveal

7 (28.0%)

3 (23.0%)

4 (33.3%)

 Extrafoveal

7 (28.0%)

7 (53.8%)

0 (0%)

  1. ETDRS Early Treatment of Diabetic Retinopathy Study, a T-test b Chi-squared test) c linear by linear association test